[First clinical experiences in therapy of hyperuricemia and hyperlipidemia with the clofibrate derivative MK 185].
作者信息
Wolfram G, Keller C, Kilani C, Zöllner N
出版信息
Verh Dtsch Ges Inn Med. 1973;79:1291-3.
PMID:4597609
Abstract
摘要
相似文献
1
[First clinical experiences in therapy of hyperuricemia and hyperlipidemia with the clofibrate derivative MK 185].
Verh Dtsch Ges Inn Med. 1973;79:1291-3.
2
[Treatment of hyperlipemia and hyperuricemia with 2-acetamidoethyl-(4-chlorophenyl)-(3-trifluoromethylphenoxy)-acetate (halofenate), a derivative of clofibrate].
Arzneimittelforschung. 1976;26(12):2221-4.
3
Halofenate: an effective hypolipemia- and hypouricemia-inducing drug.
Curr Ther Res Clin Exp. 1973 Dec;15(12):902-6.
4
5
Comparison of clofibrate with halofenate in diabetics with hyperlipidaemia.
S Afr Med J. 1977 Mar 12;51(11):348-52.
6
The metabolic spectrum of halofenate.
Int J Clin Pharmacol Biopharm. 1975 Jul;12(1-2):239-43.
7
The uricosuric action of halofenate (MK-185) in patients with hyperuricemia or uncomplicated primary gout and hyperlipidemia.
Atherosclerosis. 1973 Nov-Dec;18(3):353-62. doi: 10.1016/0021-9150(73)90065-8.
8
A two-year crossover therapeutic trial with halofenate and clofibrate.
Am J Med Sci. 1976 Nov-Dec;272(3):277-84. doi: 10.1097/00000441-197611000-00005.
9
Effect of halofenate on serum uric acid.卤芬酯对血清尿酸的影响。
Clin Pharmacol Ther. 1973 May-Jun;14(3):371-3. doi: 10.1002/cpt1973143371.
10
Effects of halofenate and probenecid on serum lipids and uric acid in hyperlipidemic, hyperuricemic adults.
Clin Pharmacol Ther. 1977 Sep;22(3):340-51. doi: 10.1002/cpt1977223340.
引用本文的文献
1
[Drug treatment of primary hyperlipoproteinemia (author's transl)].原发性高脂蛋白血症的药物治疗（作者译）
Klin Wochenschr. 1978 Feb 1;56(3):99-110. doi: 10.1007/BF01478565.
Zotero 插件